MARIKA SIMMONS: Open Payments
NPI 1154959526 · BYRAM, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$562 in 28 payments from 10 companies in 2025. Trend: 2023 $331 · 2024 $238 · 2025 $562
Food & beverage: $562
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $197 |
| Astellas Pharma US Inc | 4 | $102 |
| ABBVIE INC. | 5 | $83 |
| Lundbeck LLC | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| ABIOMED | 1 | $31 |
| Lilly USA, LLC | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Novo Nordisk Inc | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
Products named: BREZTRI, Veozah, VRAYLAR, REXULTI, MOUNJARO, UBRELVY, VYEPTI, VOQUEZNA.
Industry payments across MS — which companies pay providers there.
